Laura ShawverCEO at Silverback Therapeutics (NASDAQ: SBTX)
Dr. Shawver is an experienced Biotech executive with more than 25 years of experience in the development of drugs for cancer and other serious diseases. Since April of 2020, she is Chief Executive Officer and Director of Silverback Therapeutics™, focused on the ImmunoTAC™ platform which allows for systemic administration of drugs that are tissue directed and locally active. From November 2017 – February 2020, Dr. Shawver was President, Chief Executive Officer and Director of Synthorx, Inc, acquired by Sanofi in January 2020 for $2.5B. Prior to Synthorx, she was CEO and Director for Cleave Biosciences from 2011 – 2017 and previously, Entrepreneur in Residence for 5AM Ventures from 2010 – 2011, CEO and Director of Phenomix from 2002 – 2010, President of SUGEN Inc (acquired by Pharmacia) from 2000 after holding various positions since 1992, and a scientist at Berlex Biosciences, formerly known as Triton Biosciences, from 1989 – 1992. Dr. Shawver is the Founder of The Clearity Foundation, a nonprofit organization helping women with ovarian cancer to improve their treatment options and currently serves on the board of Relay, Nkarta, and Cleave Therapeutics. She received her PhD in Pharmacology and a BS degree in Microbiology, both from the University of Iowa.